Australia's most trusted
source of pharma news
Posted 4 August 2026 PM
Pharmanovia has inked a deal worth up to $601.9 million with Chinese biotech IMPACT Therapeutics to commercialise senaparib in 66 countries, including Australia.
The highly potent PARP1/2 inhibitor developed by the Shanghai headquartered biotech is currently on approved in China, where it also reimbursed via the National Reimbursed Drug List as a first-line maintenance therapy for adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.